Oncology

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front

5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies

Why BioNTech Is Trading Higher Today Following A Stock Upgrade From SVB Securities Analyst

5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies

Why BioNTech Is Trading Higher Today Following A Stock Upgrade From SVB Securities Analyst

Cannabotech To Manufacture Oncology Products Via Partnership With California Medical Cannabis Producer

Kymera Discloses New Development Cancer Program

Oncology Recent News

Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring

Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company

Calithera Buys Two Oncology Candidates From Takeda For $45M

Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).

Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings

Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?

AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies

Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4

Why Are Silverback Therapeutics Shares Falling On Monday?

UK's NHS Launches World's Largest Trial Of Blood Test For 50 Types

Adaptimmune Shares Encouraging Data From Solid Tumor Trial

Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay

Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma

See Why RenovoRx Stock Is Shooting Higher On Tuesday

Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications

Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates

ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty

Rafael Starts Mid-Stage Biliary Tract Cancer Trial With CPI-613 Combo Regime

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial

What's Happening With Sonnet BioTherapeutics Stock?

Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. No company-specific reports are driving up the stock price today, so it appears there are external factors at play.

Adagene Inks Third Cancer Trial Collaboration With Merck

Exelixis, Invenra Expand Oncology Pact

Merck's Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors

	
		OSZAR »